Skip to main content

Advertisement

SpringerLink
Log in

Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I–III Merkel Cell Cancer (STAMP)

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current US incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457-463.e452.

    Article  Google Scholar 

  2. Tello TL, Coggshall K, Yom SS, Yu SS. Merkel cell carcinoma: an update and review: current and future therapy. J Am Acad Dermatol. 2018;78(3):445–54.

    Article  Google Scholar 

  3. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 Blockade with Pembrolizumab in advanced Merkel-Cell Carcinoma. N Engl J Med. 2016;374(26):2542–52.

    Article  CAS  Google Scholar 

  4. Lee AY, Berman RS. The landmark series: non-melanoma skin cancers. Ann Surg Oncol. 2020;27(1):22–7.

    Article  Google Scholar 

  5. Dimitriou F, Long GV, Menzies AM. Novel adjuvant options for cutaneous melanoma. Ann Oncol. 2021;32(7):854–65.

    Article  CAS  Google Scholar 

  6. Bichakjian CK, Olencki T, Aasi SZ, et al. Merkel cell carcinoma, Version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(6):742–74.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Martha E. Teke MD, Alexander J. Rossi MD & Jonathan M. Hernandez MD

  2. Department of Plastic Surgery, Department of Immunology, Dermatology and Plastic Surgery Institute, Head and Neck Institute, Taussig Cancer Center, Lerner Research Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA

    Brian Gastman MD

Authors
  1. Martha E. Teke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander J. Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brian Gastman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jonathan M. Hernandez MD or Brian Gastman MD.

Ethics declarations

DISCLOSURE

BG reports consulting agreements with BMS, Alkermes, Castle Biosciences, NIT, IOVANCE and Instill Bio. Martha E. Teke, Alexander J. Rossi, and Jonathan M. Hernandez declare they have no conflicts of interest and no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 175 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teke, M.E., Rossi, A.J., Hernandez, J.M. et al. Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I–III Merkel Cell Cancer (STAMP). Ann Surg Oncol 29, 3379–3380 (2022). https://doi.org/10.1245/s10434-022-11498-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-11498-0

Search

Navigation